KAREN GRIFFIN: Open Payments
NPI 1881866416 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,851 in 84 payments from 22 companies in 2025. Trend: 2023 $1,750 · 2024 $2,668 · 2025 $1,851
Food & beverage: $1,851
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $524 |
| Lilly USA, LLC | 7 | $153 |
| TG Therapeutics, Inc. | 6 | $133 |
| Genentech USA, Inc. | 6 | $125 |
| Biogen, Inc. | 4 | $118 |
| MDD US Operations, LLC | 6 | $107 |
| EMD Serono, Inc. | 4 | $91 |
| Novartis Pharmaceuticals Corporation | 5 | $81 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Alexion Pharmaceuticals, Inc. | 3 | $64 |
Products named: QULIPTA, BOTOX, KISUNLA, BRIUMVI, Ocrevus, AVONEX, KESIMPTA, VYALEV.
Industry payments across IN — which companies pay providers there.
